Burden of disease matters when it comes to systemic therapy for prostate cancer.
Publication
, Journal Article
Harrison, MR; Armstrong, AJ
Published in: Eur Urol
March 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
March 2015
Volume
67
Issue
3
Start / End Page
448 / 450
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Steroid Synthesis Inhibitors
- Prostatic Neoplasms, Castration-Resistant
- Neoplasms, Hormone-Dependent
- Male
- Humans
- Health Status
- Cytochrome P-450 Enzyme Inhibitors
- Antineoplastic Agents, Hormonal
- Abiraterone Acetate
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, M. R., & Armstrong, A. J. (2015). Burden of disease matters when it comes to systemic therapy for prostate cancer. Eur Urol, 67(3), 448–450. https://doi.org/10.1016/j.eururo.2014.02.032
Harrison, Michael R., and Andrew J. Armstrong. “Burden of disease matters when it comes to systemic therapy for prostate cancer.” Eur Urol 67, no. 3 (March 2015): 448–50. https://doi.org/10.1016/j.eururo.2014.02.032.
Harrison MR, Armstrong AJ. Burden of disease matters when it comes to systemic therapy for prostate cancer. Eur Urol. 2015 Mar;67(3):448–50.
Harrison, Michael R., and Andrew J. Armstrong. “Burden of disease matters when it comes to systemic therapy for prostate cancer.” Eur Urol, vol. 67, no. 3, Mar. 2015, pp. 448–50. Pubmed, doi:10.1016/j.eururo.2014.02.032.
Harrison MR, Armstrong AJ. Burden of disease matters when it comes to systemic therapy for prostate cancer. Eur Urol. 2015 Mar;67(3):448–450.
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
March 2015
Volume
67
Issue
3
Start / End Page
448 / 450
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Steroid Synthesis Inhibitors
- Prostatic Neoplasms, Castration-Resistant
- Neoplasms, Hormone-Dependent
- Male
- Humans
- Health Status
- Cytochrome P-450 Enzyme Inhibitors
- Antineoplastic Agents, Hormonal
- Abiraterone Acetate